1. Home
  2. BDSX vs AGEN Comparison

BDSX vs AGEN Comparison

Compare BDSX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$15.49

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$2.95

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
AGEN
Founded
2005
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.3M
147.4M
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
BDSX
AGEN
Price
$15.49
$2.95
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$32.50
$14.50
AVG Volume (30 Days)
36.3K
581.5K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
$88,499,000.00
$42,877,086.00
Revenue This Year
$25.26
$107.63
Revenue Next Year
$19.15
N/A
P/E Ratio
N/A
$2.97
Revenue Growth
24.08
89.95
52 Week Low
$0.26
$2.71
52 Week High
$20.21
$7.34

Technical Indicators

Market Signals
Indicator
BDSX
AGEN
Relative Strength Index (RSI) 52.46 38.63
Support Level $14.61 $2.93
Resistance Level $16.66 $3.15
Average True Range (ATR) 0.94 0.22
MACD -0.10 -0.01
Stochastic Oscillator 24.61 13.43

Price Performance

Historical Comparison
BDSX
AGEN

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: